Topics

Merck KGaA, Pfizer say late-stage study of Bavencio in gastric cancer misses primary endpoints https://www.firstwordpharma.com/node/1679606  $PFE

08:38 EST 8 Nov 2019 | FirstWord Pharma

Merck KGaA, Pfizer say late-stage study of Bavencio in gastric cancer misses primary endpoints https://www.firstwordpharma.com/node/1679606 

Original Article: Merck KGaA, Pfizer say late-stage study of Bavencio in gastric cancer misses primary endpoints https://www.firstwordpharma.com/node/1679606  $PFE

NEXT ARTICLE

More From BioPortfolio on "Merck KGaA, Pfizer say late-stage study of Bavencio in gastric cancer misses primary endpoints https://www.firstwordpharma.com/node/1679606  $PFE"

Quick Search

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...